These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Fu Y; Buryanovskyy L; Zhang Z Biochem Biophys Res Commun; 2005 Oct; 336(1):332-8. PubMed ID: 16129418 [TBL] [Abstract][Full Text] [Related]
4. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Knox RJ; Boland MP; Friedlos F; Coles B; Southan C; Roberts JJ Biochem Pharmacol; 1988 Dec; 37(24):4671-7. PubMed ID: 3144286 [TBL] [Abstract][Full Text] [Related]
5. Combining gene and immunotherapy for prostate cancer. Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452 [TBL] [Abstract][Full Text] [Related]
6. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954. Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253 [TBL] [Abstract][Full Text] [Related]
7. Nitro reduction as an electronic switch for bioreductive drug activation. Siim BG; Denny WA; Wilson WR Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242 [TBL] [Abstract][Full Text] [Related]
8. Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex. AbuKhader M; Heap J; De Matteis C; Kellam B; Doughty SW; Minton N; Paoli M J Med Chem; 2005 Dec; 48(24):7714-9. PubMed ID: 16302811 [TBL] [Abstract][Full Text] [Related]
9. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene. Searle PF; Weedon SJ; McNeish IA; Gilligan MG; Ford MJ; Friedlos F; Springer CJ; Young LS; Kerr DJ Adv Exp Med Biol; 1998; 451():107-13. PubMed ID: 10026858 [No Abstract] [Full Text] [Related]
10. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399 [TBL] [Abstract][Full Text] [Related]
11. Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments. Schepelmann S; Spooner R; Friedlos F; Marais R Methods Mol Med; 2004; 90():279-301. PubMed ID: 14657569 [No Abstract] [Full Text] [Related]
13. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209 [TBL] [Abstract][Full Text] [Related]
14. Protonation state of F420H2 in the prodrug-activating deazaflavin dependent nitroreductase (Ddn) from Mycobacterium tuberculosis. Mohamed AE; Ahmed FH; Arulmozhiraja S; Lin CY; Taylor MC; Krausz ER; Jackson CJ; Coote ML Mol Biosyst; 2016 Apr; 12(4):1110-3. PubMed ID: 26876228 [TBL] [Abstract][Full Text] [Related]